Potential benefits of GLP-1 receptor agonist in dialysis patients with type 2 diabetes: the need for comprehensive pharmacokinetic and hemodialysis analyses

Potential benefits of GLP-1 receptor agonist in dialysis patients with type 2 diabetes: the need for comprehensive pharmacokinetic and hemodialysis analyses

Abstract The 2022 KDIGO guideline for diabetes management in patients with chronic kidney disease (CKD) had endorsed the use of GLP-1 receptor agonists (GLP-1RAs) for patients with CKD and type 2 diabetes who did not achieve optimal glycemic target with maximally tolerated metformin and sodium-gluco...

Full description

Saved in:
Bibliographic Details
Main Authors: Hsuan-Wen Lai, Jui-Yi Chen, Vin-Cent Wu, Chun Yin See
Format: Article
Language:English
Published: BMC 2025-03-01
Series:Cardiovascular Diabetology
Subjects:
GLP-1 receptor agonist
Type 2 diabetes
Dialysis
Pharmacokinetics
Online Access:https://doi.org/10.1186/s12933-024-02543-1
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12933-024-02543-1

Similar Items